{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:28:19Z","timestamp":1788956899169,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T00:00:00Z","timestamp":1708646400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cambodia aims to eliminate all forms of malaria by 2025. In 2020, 90% of all malaria cases were <jats:italic>Plasmodium vivax.<\/jats:italic> Thus, preventing <jats:italic>P<\/jats:italic>. <jats:italic>vivax<\/jats:italic> and relapse malaria is a top priority for elimination. 14-day primaquine, a World Health Organization-recommended radical cure treatment regimen, specifically targets dormant hypnozoites in the liver to prevent relapse. Cambodia introduced <jats:italic>P. vivax<\/jats:italic> radical cure with primaquine after glucose-6-phosphate dehydrogenase (G6PD) qualitative testing in 2019. This paper presents Cambodia\u2019s radical cure Phase I implementation results and assesses the safety, effectiveness, and feasibility of the programme prior to nationwide scale up.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Phase I implementation was carried out in 88 select health facilities (HFs) across four provinces. Males over 20kgs with confirmed <jats:italic>P. vivax<\/jats:italic> or mixed (<jats:italic>P. vivax<\/jats:italic> and <jats:italic>Plasmodium falciparum<\/jats:italic>) infections were enrolled. A descriptive analysis evaluated the following: successful referral to health facilities, G6PD testing results, and self-reported 14-day treatment adherence. <jats:italic>P. vivax<\/jats:italic> incidence was compared before and after radical cure rollout and a controlled interrupted time series analysis compared the estimated relapse rate between implementation and non-implementation provinces before and after radical cure.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In the 4 provinces from November 2019 to December 2020, 3,239 <jats:italic>P. vivax<\/jats:italic>\/mixed infections were reported, 1,282 patients underwent G6PD deficiency testing, and 959 patients received radical cure, achieving 29.6% radical cure coverage among all <jats:italic>P. vivax<\/jats:italic>\/mixed cases and 98.8% coverage among G6PD normal patients. Among those who initiated radical cure, 747 patients (78%) completed treatment. Six patients reported side effects. In implementation provinces, an average 31.8 relapse cases per month were estimated signaling a 90% (286 cases) reduction in relapse compared to what would be expected if radical cure was not implemented.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p><jats:italic>Plasmodium vivax<\/jats:italic> radical cure is a crucial tool for malaria elimination in Cambodia. The high coverage of radical cure initiation and adherence among G6PD normal patients demonstrated the high feasibility of providing radical cure at point of care in Cambodia. Incomplete referral from community to HFs and limited capacity of HF staff to conduct G6PD testing in high burden areas led to lower coverage of G6PD testing. Phase I implementation informed approaches to improve referral completion and patient adherence during the nationwide expansion of radical cure in 2021.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12936-024-04884-4","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T15:03:12Z","timestamp":1708700592000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Radical cure for Plasmodium vivax malaria after G6PD qualitative testing in four provinces in Cambodia, results from Phase I implementation"],"prefix":"10.1186","volume":"23","author":[{"given":"Dysoley","family":"Lek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Cheng","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jillian","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siv","family":"Sovannaroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Voeurng","family":"Bunreth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prak","family":"Vonn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Or","family":"Vannthen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tol","family":"Bunkea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Top","family":"Samphornarann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nguon","family":"Sokomar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mak","family":"Sarath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soy Ty","family":"Kheang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle K.","family":"Burbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayme","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huy","family":"Rekol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,23]]},"reference":[{"key":"4884_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0003595","volume":"9","author":"AI Adekunle","year":"2015","unstructured":"Adekunle AI, Pinkevych M, McGready R, Luxemburger C, White LJ, Nosten F, et al. Modeling the dynamics of Plasmodium vivax infection and hypnozoite reactivation in vivo. PLoS Negl Trop Dis. 2015;9: e0003595.","journal-title":"PLoS Negl Trop Dis"},{"key":"4884_CR2","doi-asserted-by":"publisher","first-page":"5595","DOI":"10.1038\/s41467-019-13412-x","volume":"10","author":"AR Taylor","year":"2019","unstructured":"Taylor AR, Watson JA, Chu CS, Puaprasert K, Duanguppama J, Day NPJ, et al. Resolving the cause of recurrent Plasmodium vivax malaria probabilistically. Nat Commun. 2019;10:5595.","journal-title":"Nat Commun"},{"key":"4884_CR3","doi-asserted-by":"publisher","first-page":"e01888","DOI":"10.1128\/mBio.01888-17","volume":"9","author":"J Popovici","year":"2018","unstructured":"Popovici J, Friedrich LR, Kim S, Bin S, Run V, Lek D, et al. Genomic analyses reveal the common occurrence and complexity of Plasmodium vivax relapses in Cambodia. MBio. 2018;9:e01888-e1917.","journal-title":"MBio"},{"key":"4884_CR4","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/1475-2875-13-144","volume":"13","author":"KE Battle","year":"2014","unstructured":"Battle KE, Karhunen MS, Bhatt S, Gething PW, Howes RE, Golding N, et al. Geographical variation in Plasmodium vivax relapse. Malar J. 2014;13:144.","journal-title":"Malar J"},{"key":"4884_CR5","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S0140-6736(08)60073-2","volume":"371","author":"MD Cappellini","year":"2008","unstructured":"Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet. 2008;371:64\u201374.","journal-title":"Lancet"},{"key":"4884_CR6","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1086\/424663","volume":"39","author":"JK Baird","year":"2004","unstructured":"Baird JK, Hoffman SL. Primaquine therapy for malaria. Clin Infect Dis. 2004;39:1336\u201345.","journal-title":"Clin Infect Dis"},{"key":"4884_CR7","volume-title":"Guidelines for the treatment of malaria","author":"WHO","year":"2021","unstructured":"WHO. Guidelines for the treatment of malaria. 2nd ed. Geneva: World Health Organization; 2021.","edition":"2"},{"key":"4884_CR8","volume-title":"Testing for G6PD deficiency for safe use of primaquine in radical cure of P. vivax and P. ovale malaria","author":"WHO","year":"2016","unstructured":"WHO. Testing for G6PD deficiency for safe use of primaquine in radical cure of P. vivax and P. ovale malaria. Geneva: World Health Organization; 2016."},{"key":"4884_CR9","volume-title":"Guide to G6PD deficiency rapid diagnostic testing to support P. vivax radical cure","author":"WHO","year":"2018","unstructured":"WHO. Guide to G6PD deficiency rapid diagnostic testing to support P. vivax radical cure. Geneva: World Health Organization; 2018."},{"key":"4884_CR10","unstructured":"Malaria Information System (MIS) [Internet]. 2021."},{"key":"4884_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001339","volume":"9","author":"RE Howes","year":"2012","unstructured":"Howes RE, Piel FB, Patil AP, Nyangiri OA, Gething PW, Dewi M, et al. G6PD deficiency prevalence and estimates of affected populations in malaria endemic countries: a geostatistical model-based map. PLoS Med. 2012;9: e1001339.","journal-title":"PLoS Med"},{"key":"4884_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0125796","volume":"10","author":"D Adu-Gyasi","year":"2015","unstructured":"Adu-Gyasi D, Asante KP, Newton S, Dosoo D, Amoako S, Adjei G, et al. Evaluation of the diagnostic accuracy of CareStart G6PD deficiency rapid diagnostic test (RDT) in a malaria endemic area in Ghana. Africa PLoS One. 2015;10: e0125796.","journal-title":"Africa PLoS One"},{"key":"4884_CR13","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1186\/1475-2875-10-297","volume":"10","author":"NJ White","year":"2011","unstructured":"White NJ. Determinants of relapse periodicity in Plasmodium vivax malaria. Malar J. 2011;10:297.","journal-title":"Malar J"},{"key":"4884_CR14","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12916-020-1497-0","volume":"18","author":"S Dini","year":"2020","unstructured":"Dini S, Douglas NM, Poespoprodjo JR, Kenangalem E, Sugiarto P, Plumb ID, et al. The risk of morbidity and mortality following recurrent malaria in Papua, Indonesia: a retrospective cohort study. BMC Med. 2020;18:28.","journal-title":"BMC Med"},{"key":"4884_CR15","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s12936-021-03743-w","volume":"20","author":"N Engel","year":"2021","unstructured":"Engel N, Ghergu C, Matin MA, Kibria MG, Thriemer K, Price RN, et al. Implementing radical cure diagnostics for malaria: user perspectives on G6PD testing in Bangladesh. Malar J. 2021;20:217.","journal-title":"Malar J"},{"key":"4884_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0008838","volume":"14","author":"K Thriemer","year":"2020","unstructured":"Thriemer K, Poespoprodjo JR, Kenangalem E, Douglas NM, Sugiarto P, Anstey NM, et al. The risk of adverse clinical outcomes following treatment of Plasmodium vivax malaria with and without primaquine in Papua. Indonesia PLoS Negl Trop Dis. 2020;14: e0008838.","journal-title":"Indonesia PLoS Negl Trop Dis"},{"key":"4884_CR17","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.4269\/ajtmh.2010.09-0521","volume":"82","author":"KP Grietens","year":"2010","unstructured":"Grietens KP, Soto V, Erhart A, Ribera JM, Toomer E, Tenorio A, et al. Adherence to 7-day primaquine treatment for the radical cure of P. vivax in the Peruvian Amazon. Am J Trop Med Hyg. 2010;82:1017\u201323.","journal-title":"Am J Trop Med Hyg."},{"key":"4884_CR18","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s41182-018-0110-0","volume":"46","author":"NYY Linn","year":"2018","unstructured":"Linn NYY, Tripathy JP, Maung TM, Saw KK, Maw LYW, Thapa B, et al. How are the village health volunteers deliver malaria testing and treatment services and what are the challenges they are facing? A mixed methods study in Myanmar. Trop Med Health. 2018;46:28.","journal-title":"Trop Med Health"},{"key":"4884_CR19","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3329\/jhpn.v27i1.3313","volume":"27","author":"N Khantikul","year":"2009","unstructured":"Khantikul N, Butraporn P, Kim HS, Leemingsawat S, Tempongko MA, Suwonkerd W. Adherence to antimalarial drug therapy among vivax malaria patients in northern Thailand. J Health Popul Nutr. 2009;27:4\u201313.","journal-title":"J Health Popul Nutr"},{"key":"4884_CR20","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.actatropica.2015.08.008","volume":"152","author":"A Cheoymang","year":"2015","unstructured":"Cheoymang A, Ruenweerayut R, Muhamad P, Rungsihirunrat K, Na-Bangchang K. Patients\u2019 adherence and clinical effectiveness of a 14-day course of primaquine when given with a 3-day chloroquine in patients with Plasmodium vivax at the Thai-Myanmar border. Acta Trop. 2015;152:151\u20136.","journal-title":"Acta Trop"},{"key":"4884_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0084555","volume":"9","author":"K Bruxvoort","year":"2014","unstructured":"Bruxvoort K, Goodman C, Kachur SP, Schellenberg D. How patients take malaria treatment: a systematic review of the literature on adherence to antimalarial drugs. PLoS ONE. 2014;9: e84555.","journal-title":"PLoS ONE"},{"key":"4884_CR22","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1007\/s13142-015-0315-2","volume":"5","author":"MJ Stirratt","year":"2015","unstructured":"Stirratt MJ, Dunbar-Jacob J, Crane HM, Simoni JM, Czajkowski S, Hilliard ME, et al. Self-report measures of medication adherence behavior: recommendations on optimal use. Transl Behav Med. 2015;5:470\u201382.","journal-title":"Transl Behav Med"},{"key":"4884_CR23","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s12936-018-2380-8","volume":"17","author":"K Thriemer","year":"2018","unstructured":"Thriemer K, Bobogare A, Ley B, Gudo CS, Alam MS, Anstey NM, et al. Quantifying primaquine effectiveness and improving adherence: a round table discussion of the APMEN Vivax Working Group. Malar J. 2018;17:241.","journal-title":"Malar J"},{"key":"4884_CR24","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/S0035-9203(03)00041-5","volume":"98","author":"T Leslie","year":"2004","unstructured":"Leslie T, Rab MA, Ahmadzai H, Durrani N, Fayaz M, Kolaczinski J, et al. Compliance with 14-day primaquine therapy for radical cure of vivax malaria\u2013a randomized placebo-controlled trial comparing unsupervised with supervised treatment. Trans R Soc Trop Med Hyg. 2004;98:168\u201373.","journal-title":"Trans R Soc Trop Med Hyg"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-024-04884-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-024-04884-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-024-04884-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T15:07:27Z","timestamp":1708700847000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-024-04884-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,23]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4884"],"URL":"https:\/\/doi.org\/10.1186\/s12936-024-04884-4","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,23]]},"assertion":[{"value":"24 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have declared that no competing interests exist.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"56"}}